KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Payables: 2014-2024

Historic Payables for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Dec 2024 value amounting to $5.2 million.

  • Aurinia Pharmaceuticals' Payables fell 96.10% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year decrease of 91.10%. This contributed to the annual value of $5.2 million for FY2024, which is 19.88% up from last year.
  • Aurinia Pharmaceuticals' Payables amounted to $5.2 million in FY2024, which was up 19.88% from $4.3 million recorded in FY2023.
  • In the past 5 years, Aurinia Pharmaceuticals' Payables registered a high of $40.0 million during FY2022, and its lowest value of $4.3 million during FY2023.
  • In the last 3 years, Aurinia Pharmaceuticals' Payables had a median value of $5.2 million in 2024 and averaged $16.5 million.
  • In the last 5 years, Aurinia Pharmaceuticals' Payables soared by 121.86% in 2020 and then tumbled by 89.18% in 2023.
  • Yearly analysis of 5 years shows Aurinia Pharmaceuticals' Payables stood at $24.8 million in 2020, then skyrocketed by 40.93% to $34.9 million in 2021, then rose by 14.43% to $40.0 million in 2022, then slumped by 89.18% to $4.3 million in 2023, then increased by 19.88% to $5.2 million in 2024.